http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Mon, 18 May 2026 08:45:18 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/FDA/Dogwood+Therapeutics+begins+12-week+extension+study+for+pain+drug/26510875.html <p>Dogwood Therapeutics Inc. (NASDAQ: DWTX) announced the start of a 12-week extension study for its Halneuron drug to treat chemotherapy-induced neuropathic pain. The open-label trial will enroll patients who completed the ongoing 4-week Phase 2b study.</p> <p>The extension study follows a positive interim assessment that showed Halneuron demonstrated treatment effects versus placebo in the 4-week trial. The company submitted plans to the FDA to support the extension study, which will evaluate safety and efficacy of continued Halneuron treatment over three months using various dosing regimens.</p> <p>Data from the extension trial will be included in Dogwood's submission package to the FDA to support http://www.streetinsider.com/FDA/Dogwood+Therapeutics+begins+12-week+extension+study+for+pain+drug/26510875.html Mon, 18 May 2026 08:45:18 -0400 A.50216777 A.60001765 DWTX O.00793356 O.20738543 O.54516537 http://www.streetinsider.com/FDA/Dogwood+Therapeutics+begins+12-week+extension+study+for+pain+drug/26510875.html <p>Dogwood Therapeutics Inc. (NASDAQ: DWTX) announced the start of a 12-week extension study for its Halneuron drug to treat chemotherapy-induced neuropathic pain. The open-label trial will enroll patients who completed the ongoing 4-week Phase 2b study.</p> <p>The extension study follows a positive interim assessment that showed Halneuron demonstrated treatment effects versus placebo in the 4-week trial. The company submitted plans to the FDA to support the extension study, which will evaluate safety and efficacy of continued Halneuron treatment over three months using various dosing regimens.</p> <p>Data from the extension trial will be included in Dogwood's submission package to the FDA to support http://www.streetinsider.com/FDA/Dogwood+Therapeutics+begins+12-week+extension+study+for+pain+drug/26510875.html Mon, 18 May 2026 08:45:18 -0400 A.50216777 A.60001765 DWTX O.00793356 O.20738543 O.54516537 http://www.streetinsider.com/FDA/Dogwood+Therapeutics+begins+12-week+extension+study+for+pain+drug/26510875.html <p>Dogwood Therapeutics Inc. (NASDAQ: DWTX) announced the start of a 12-week extension study for its Halneuron drug to treat chemotherapy-induced neuropathic pain. The open-label trial will enroll patients who completed the ongoing 4-week Phase 2b study.</p> <p>The extension study follows a positive interim assessment that showed Halneuron demonstrated treatment effects versus placebo in the 4-week trial. The company submitted plans to the FDA to support the extension study, which will evaluate safety and efficacy of continued Halneuron treatment over three months using various dosing regimens.</p> <p>Data from the extension trial will be included in Dogwood's submission package to the FDA to support http://www.streetinsider.com/FDA/Dogwood+Therapeutics+begins+12-week+extension+study+for+pain+drug/26510875.html Mon, 18 May 2026 08:45:18 -0400 A.50216777 A.60001765 DWTX O.00793356 O.20738543 O.54516537 http://www.streetinsider.com/FDA/Dogwood+Therapeutics+begins+12-week+extension+study+for+pain+drug/26510875.html <p>Dogwood Therapeutics Inc. (NASDAQ: DWTX) announced the start of a 12-week extension study for its Halneuron drug to treat chemotherapy-induced neuropathic pain. The open-label trial will enroll patients who completed the ongoing 4-week Phase 2b study.</p> <p>The extension study follows a positive interim assessment that showed Halneuron demonstrated treatment effects versus placebo in the 4-week trial. The company submitted plans to the FDA to support the extension study, which will evaluate safety and efficacy of continued Halneuron treatment over three months using various dosing regimens.</p> <p>Data from the extension trial will be included in Dogwood's submission package to the FDA to support http://www.streetinsider.com/FDA/Dogwood+Therapeutics+begins+12-week+extension+study+for+pain+drug/26510875.html Mon, 18 May 2026 08:45:18 -0400 A.50216777 A.60001765 DWTX O.00793356 O.20738543 O.54516537 http://www.streetinsider.com/FDA/Dogwood+Therapeutics+begins+12-week+extension+study+for+pain+drug/26510875.html <p>Dogwood Therapeutics Inc. (NASDAQ: DWTX) announced the start of a 12-week extension study for its Halneuron drug to treat chemotherapy-induced neuropathic pain. The open-label trial will enroll patients who completed the ongoing 4-week Phase 2b study.</p> <p>The extension study follows a positive interim assessment that showed Halneuron demonstrated treatment effects versus placebo in the 4-week trial. The company submitted plans to the FDA to support the extension study, which will evaluate safety and efficacy of continued Halneuron treatment over three months using various dosing regimens.</p> <p>Data from the extension trial will be included in Dogwood's submission package to the FDA to support http://www.streetinsider.com/FDA/Dogwood+Therapeutics+begins+12-week+extension+study+for+pain+drug/26510875.html Mon, 18 May 2026 08:45:18 -0400 A.50216777 A.60001765 DWTX O.00793356 O.20738543 O.54516537 http://www.streetinsider.com/FDA/Dogwood+Therapeutics+begins+12-week+extension+study+for+pain+drug/26510875.html <p>Dogwood Therapeutics Inc. (NASDAQ: DWTX) announced the start of a 12-week extension study for its Halneuron drug to treat chemotherapy-induced neuropathic pain. The open-label trial will enroll patients who completed the ongoing 4-week Phase 2b study.</p> <p>The extension study follows a positive interim assessment that showed Halneuron demonstrated treatment effects versus placebo in the 4-week trial. The company submitted plans to the FDA to support the extension study, which will evaluate safety and efficacy of continued Halneuron treatment over three months using various dosing regimens.</p> <p>Data from the extension trial will be included in Dogwood's submission package to the FDA to support http://www.streetinsider.com/FDA/Dogwood+Therapeutics+begins+12-week+extension+study+for+pain+drug/26510875.html Mon, 18 May 2026 08:45:18 -0400 A.50216777 A.60001765 DWTX O.00793356 O.20738543 O.54516537 http://www.streetinsider.com/Press+Releases/Dogwood+Therapeutics+Announces+Commencement+of+Halneuron%C2%AE+Chemotherapy+Induced+Neuropathic+Pain+Phase+2b+Long+Term+Extension+Study/26510873.html <p align="center"><em>New study to assess Halneuron</em>®<em> pain reduction effect over three months of treatment, additional safety data to bolster planned end of Phase 2 FDA submission package</em></p> <p align="center"><em>Patients completing the ongoing Halneuron</em>®<em> 4-week CINP Phase 2b study are now eligible to enroll in the new 12-week open-label follow-on trial </em></p> <p align="justify">ALPHARETTA, Ga., May 18, 2026 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (NASDAQ: DWTX) (“Dogwood” or the “Company”), a biopharmaceutical company developing first-in-class, non-opioid medicines to treat pain and neuropathy, today announced commencement of a new Halneuron® chemotherapy induced neuropathic pain (“CINP”) phase 2b extension http://www.streetinsider.com/Press+Releases/Dogwood+Therapeutics+Announces+Commencement+of+Halneuron%C2%AE+Chemotherapy+Induced+Neuropathic+Pain+Phase+2b+Long+Term+Extension+Study/26510873.html Mon, 18 May 2026 08:45:00 -0400 A.50216777 A.60001765 DWTX O.00793356 O.20738543 O.54516537 http://www.streetinsider.com/Press+Releases/Dogwood+Therapeutics+Announces+Commencement+of+Halneuron%C2%AE+Chemotherapy+Induced+Neuropathic+Pain+Phase+2b+Long+Term+Extension+Study/26510873.html <p align="center"><em>New study to assess Halneuron</em>®<em> pain reduction effect over three months of treatment, additional safety data to bolster planned end of Phase 2 FDA submission package</em></p> <p align="center"><em>Patients completing the ongoing Halneuron</em>®<em> 4-week CINP Phase 2b study are now eligible to enroll in the new 12-week open-label follow-on trial </em></p> <p align="justify">ALPHARETTA, Ga., May 18, 2026 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (NASDAQ: DWTX) (“Dogwood” or the “Company”), a biopharmaceutical company developing first-in-class, non-opioid medicines to treat pain and neuropathy, today announced commencement of a new Halneuron® chemotherapy induced neuropathic pain (“CINP”) phase 2b extension http://www.streetinsider.com/Press+Releases/Dogwood+Therapeutics+Announces+Commencement+of+Halneuron%C2%AE+Chemotherapy+Induced+Neuropathic+Pain+Phase+2b+Long+Term+Extension+Study/26510873.html Mon, 18 May 2026 08:45:00 -0400 A.50216777 A.60001765 DWTX O.00793356 O.20738543 O.54516537 http://www.streetinsider.com/Press+Releases/Dogwood+Therapeutics+Announces+Commencement+of+Halneuron%C2%AE+Chemotherapy+Induced+Neuropathic+Pain+Phase+2b+Long+Term+Extension+Study/26510873.html <p align="center"><em>New study to assess Halneuron</em>®<em> pain reduction effect over three months of treatment, additional safety data to bolster planned end of Phase 2 FDA submission package</em></p> <p align="center"><em>Patients completing the ongoing Halneuron</em>®<em> 4-week CINP Phase 2b study are now eligible to enroll in the new 12-week open-label follow-on trial </em></p> <p align="justify">ALPHARETTA, Ga., May 18, 2026 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (NASDAQ: DWTX) (“Dogwood” or the “Company”), a biopharmaceutical company developing first-in-class, non-opioid medicines to treat pain and neuropathy, today announced commencement of a new Halneuron® chemotherapy induced neuropathic pain (“CINP”) phase 2b extension http://www.streetinsider.com/Press+Releases/Dogwood+Therapeutics+Announces+Commencement+of+Halneuron%C2%AE+Chemotherapy+Induced+Neuropathic+Pain+Phase+2b+Long+Term+Extension+Study/26510873.html Mon, 18 May 2026 08:45:00 -0400 A.50216777 A.60001765 DWTX O.00793356 O.20738543 O.54516537 http://www.streetinsider.com/Press+Releases/Dogwood+Therapeutics+Announces+Commencement+of+Halneuron%C2%AE+Chemotherapy+Induced+Neuropathic+Pain+Phase+2b+Long+Term+Extension+Study/26510873.html <p align="center"><em>New study to assess Halneuron</em>®<em> pain reduction effect over three months of treatment, additional safety data to bolster planned end of Phase 2 FDA submission package</em></p> <p align="center"><em>Patients completing the ongoing Halneuron</em>®<em> 4-week CINP Phase 2b study are now eligible to enroll in the new 12-week open-label follow-on trial </em></p> <p align="justify">ALPHARETTA, Ga., May 18, 2026 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (NASDAQ: DWTX) (“Dogwood” or the “Company”), a biopharmaceutical company developing first-in-class, non-opioid medicines to treat pain and neuropathy, today announced commencement of a new Halneuron® chemotherapy induced neuropathic pain (“CINP”) phase 2b extension http://www.streetinsider.com/Press+Releases/Dogwood+Therapeutics+Announces+Commencement+of+Halneuron%C2%AE+Chemotherapy+Induced+Neuropathic+Pain+Phase+2b+Long+Term+Extension+Study/26510873.html Mon, 18 May 2026 08:45:00 -0400 A.50216777 A.60001765 DWTX O.00793356 O.20738543 O.54516537 http://www.streetinsider.com/Press+Releases/Dogwood+Therapeutics+Announces+Commencement+of+Halneuron%C2%AE+Chemotherapy+Induced+Neuropathic+Pain+Phase+2b+Long+Term+Extension+Study/26510873.html <p align="center"><em>New study to assess Halneuron</em>®<em> pain reduction effect over three months of treatment, additional safety data to bolster planned end of Phase 2 FDA submission package</em></p> <p align="center"><em>Patients completing the ongoing Halneuron</em>®<em> 4-week CINP Phase 2b study are now eligible to enroll in the new 12-week open-label follow-on trial </em></p> <p align="justify">ALPHARETTA, Ga., May 18, 2026 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (NASDAQ: DWTX) (“Dogwood” or the “Company”), a biopharmaceutical company developing first-in-class, non-opioid medicines to treat pain and neuropathy, today announced commencement of a new Halneuron® chemotherapy induced neuropathic pain (“CINP”) phase 2b extension http://www.streetinsider.com/Press+Releases/Dogwood+Therapeutics+Announces+Commencement+of+Halneuron%C2%AE+Chemotherapy+Induced+Neuropathic+Pain+Phase+2b+Long+Term+Extension+Study/26510873.html Mon, 18 May 2026 08:45:00 -0400 A.50216777 A.60001765 DWTX O.00793356 O.20738543 O.54516537 http://www.streetinsider.com/Press+Releases/Dogwood+Therapeutics+Announces+Commencement+of+Halneuron%C2%AE+Chemotherapy+Induced+Neuropathic+Pain+Phase+2b+Long+Term+Extension+Study/26510873.html <p align="center"><em>New study to assess Halneuron</em>®<em> pain reduction effect over three months of treatment, additional safety data to bolster planned end of Phase 2 FDA submission package</em></p> <p align="center"><em>Patients completing the ongoing Halneuron</em>®<em> 4-week CINP Phase 2b study are now eligible to enroll in the new 12-week open-label follow-on trial </em></p> <p align="justify">ALPHARETTA, Ga., May 18, 2026 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (NASDAQ: DWTX) (“Dogwood” or the “Company”), a biopharmaceutical company developing first-in-class, non-opioid medicines to treat pain and neuropathy, today announced commencement of a new Halneuron® chemotherapy induced neuropathic pain (“CINP”) phase 2b extension http://www.streetinsider.com/Press+Releases/Dogwood+Therapeutics+Announces+Commencement+of+Halneuron%C2%AE+Chemotherapy+Induced+Neuropathic+Pain+Phase+2b+Long+Term+Extension+Study/26510873.html Mon, 18 May 2026 08:45:00 -0400 A.50216777 A.60001765 DWTX O.00793356 O.20738543 O.54516537 http://www.streetinsider.com/Globe+Newswire/Dogwood+Therapeutics+Announces+Commencement+of+Halneuron%C2%AE+Chemotherapy+Induced+Neuropathic+Pain+Phase+2b+Long+Term+Extension+Study/26510873.html <p align="center"><em>New study to assess Halneuron</em>®<em> pain reduction effect over three months of treatment, additional safety data to bolster planned end of Phase 2 FDA submission package</em></p> <p align="center"><em>Patients completing the ongoing Halneuron</em>®<em> 4-week CINP Phase 2b study are now eligible to enroll in the new 12-week open-label follow-on trial </em></p> <p align="justify">ALPHARETTA, Ga., May 18, 2026 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (NASDAQ: DWTX) (“Dogwood” or the “Company”), a biopharmaceutical company developing first-in-class, non-opioid medicines to treat pain and neuropathy, today announced commencement of a new Halneuron® chemotherapy induced neuropathic pain (“CINP”) phase 2b extension http://www.streetinsider.com/Globe+Newswire/Dogwood+Therapeutics+Announces+Commencement+of+Halneuron%C2%AE+Chemotherapy+Induced+Neuropathic+Pain+Phase+2b+Long+Term+Extension+Study/26510873.html Mon, 18 May 2026 08:45:00 -0400 A.50216777 A.60001765 DWTX O.00793356 O.20738543 O.54516537 http://www.streetinsider.com/Globe+Newswire/Dogwood+Therapeutics+Announces+Commencement+of+Halneuron%C2%AE+Chemotherapy+Induced+Neuropathic+Pain+Phase+2b+Long+Term+Extension+Study/26510873.html <p align="center"><em>New study to assess Halneuron</em>®<em> pain reduction effect over three months of treatment, additional safety data to bolster planned end of Phase 2 FDA submission package</em></p> <p align="center"><em>Patients completing the ongoing Halneuron</em>®<em> 4-week CINP Phase 2b study are now eligible to enroll in the new 12-week open-label follow-on trial </em></p> <p align="justify">ALPHARETTA, Ga., May 18, 2026 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (NASDAQ: DWTX) (“Dogwood” or the “Company”), a biopharmaceutical company developing first-in-class, non-opioid medicines to treat pain and neuropathy, today announced commencement of a new Halneuron® chemotherapy induced neuropathic pain (“CINP”) phase 2b extension http://www.streetinsider.com/Globe+Newswire/Dogwood+Therapeutics+Announces+Commencement+of+Halneuron%C2%AE+Chemotherapy+Induced+Neuropathic+Pain+Phase+2b+Long+Term+Extension+Study/26510873.html Mon, 18 May 2026 08:45:00 -0400 A.50216777 A.60001765 DWTX O.00793356 O.20738543 O.54516537 http://www.streetinsider.com/Globe+Newswire/Dogwood+Therapeutics+Announces+Commencement+of+Halneuron%C2%AE+Chemotherapy+Induced+Neuropathic+Pain+Phase+2b+Long+Term+Extension+Study/26510873.html <p align="center"><em>New study to assess Halneuron</em>®<em> pain reduction effect over three months of treatment, additional safety data to bolster planned end of Phase 2 FDA submission package</em></p> <p align="center"><em>Patients completing the ongoing Halneuron</em>®<em> 4-week CINP Phase 2b study are now eligible to enroll in the new 12-week open-label follow-on trial </em></p> <p align="justify">ALPHARETTA, Ga., May 18, 2026 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (NASDAQ: DWTX) (“Dogwood” or the “Company”), a biopharmaceutical company developing first-in-class, non-opioid medicines to treat pain and neuropathy, today announced commencement of a new Halneuron® chemotherapy induced neuropathic pain (“CINP”) phase 2b extension http://www.streetinsider.com/Globe+Newswire/Dogwood+Therapeutics+Announces+Commencement+of+Halneuron%C2%AE+Chemotherapy+Induced+Neuropathic+Pain+Phase+2b+Long+Term+Extension+Study/26510873.html Mon, 18 May 2026 08:45:00 -0400 A.50216777 A.60001765 DWTX O.00793356 O.20738543 O.54516537 http://www.streetinsider.com/Globe+Newswire/Dogwood+Therapeutics+Announces+Commencement+of+Halneuron%C2%AE+Chemotherapy+Induced+Neuropathic+Pain+Phase+2b+Long+Term+Extension+Study/26510873.html <p align="center"><em>New study to assess Halneuron</em>®<em> pain reduction effect over three months of treatment, additional safety data to bolster planned end of Phase 2 FDA submission package</em></p> <p align="center"><em>Patients completing the ongoing Halneuron</em>®<em> 4-week CINP Phase 2b study are now eligible to enroll in the new 12-week open-label follow-on trial </em></p> <p align="justify">ALPHARETTA, Ga., May 18, 2026 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (NASDAQ: DWTX) (“Dogwood” or the “Company”), a biopharmaceutical company developing first-in-class, non-opioid medicines to treat pain and neuropathy, today announced commencement of a new Halneuron® chemotherapy induced neuropathic pain (“CINP”) phase 2b extension http://www.streetinsider.com/Globe+Newswire/Dogwood+Therapeutics+Announces+Commencement+of+Halneuron%C2%AE+Chemotherapy+Induced+Neuropathic+Pain+Phase+2b+Long+Term+Extension+Study/26510873.html Mon, 18 May 2026 08:45:00 -0400 A.50216777 A.60001765 DWTX O.00793356 O.20738543 O.54516537 http://www.streetinsider.com/Globe+Newswire/Dogwood+Therapeutics+Announces+Commencement+of+Halneuron%C2%AE+Chemotherapy+Induced+Neuropathic+Pain+Phase+2b+Long+Term+Extension+Study/26510873.html <p align="center"><em>New study to assess Halneuron</em>®<em> pain reduction effect over three months of treatment, additional safety data to bolster planned end of Phase 2 FDA submission package</em></p> <p align="center"><em>Patients completing the ongoing Halneuron</em>®<em> 4-week CINP Phase 2b study are now eligible to enroll in the new 12-week open-label follow-on trial </em></p> <p align="justify">ALPHARETTA, Ga., May 18, 2026 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (NASDAQ: DWTX) (“Dogwood” or the “Company”), a biopharmaceutical company developing first-in-class, non-opioid medicines to treat pain and neuropathy, today announced commencement of a new Halneuron® chemotherapy induced neuropathic pain (“CINP”) phase 2b extension http://www.streetinsider.com/Globe+Newswire/Dogwood+Therapeutics+Announces+Commencement+of+Halneuron%C2%AE+Chemotherapy+Induced+Neuropathic+Pain+Phase+2b+Long+Term+Extension+Study/26510873.html Mon, 18 May 2026 08:45:00 -0400 A.50216777 A.60001765 DWTX O.00793356 O.20738543 O.54516537 http://www.streetinsider.com/Globe+Newswire/Dogwood+Therapeutics+Announces+Commencement+of+Halneuron%C2%AE+Chemotherapy+Induced+Neuropathic+Pain+Phase+2b+Long+Term+Extension+Study/26510873.html <p align="center"><em>New study to assess Halneuron</em>®<em> pain reduction effect over three months of treatment, additional safety data to bolster planned end of Phase 2 FDA submission package</em></p> <p align="center"><em>Patients completing the ongoing Halneuron</em>®<em> 4-week CINP Phase 2b study are now eligible to enroll in the new 12-week open-label follow-on trial </em></p> <p align="justify">ALPHARETTA, Ga., May 18, 2026 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (NASDAQ: DWTX) (“Dogwood” or the “Company”), a biopharmaceutical company developing first-in-class, non-opioid medicines to treat pain and neuropathy, today announced commencement of a new Halneuron® chemotherapy induced neuropathic pain (“CINP”) phase 2b extension http://www.streetinsider.com/Globe+Newswire/Dogwood+Therapeutics+Announces+Commencement+of+Halneuron%C2%AE+Chemotherapy+Induced+Neuropathic+Pain+Phase+2b+Long+Term+Extension+Study/26510873.html Mon, 18 May 2026 08:45:00 -0400 A.50216777 A.60001765 DWTX O.00793356 O.20738543 O.54516537 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Dogwood+Therapeutics%2C++++++++++++++++++Filed+by%3A+ARMISTICE+CAPITAL%2C+LLC/26502019.html si-local-file:///var/storage/secattach/20260515/26502019.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Dogwood+Therapeutics%2C++++++++++++++++++Filed+by%3A+ARMISTICE+CAPITAL%2C+LLC/26502019.html Fri, 15 May 2026 11:13:00 -0400 DWTX O.00793356 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Dogwood+Therapeutics%2C++++++++++++++++++Filed+by%3A+ARMISTICE+CAPITAL%2C+LLC/26502019.html si-local-file:///var/storage/secattach/20260515/26502019.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Dogwood+Therapeutics%2C++++++++++++++++++Filed+by%3A+ARMISTICE+CAPITAL%2C+LLC/26502019.html Fri, 15 May 2026 11:13:00 -0400 DWTX O.00793356 http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Dogwood+Therapeutics%2C+++++For%3A+Mar+31/26500682.html si-local-file:///var/storage/secattach/20260515/26500682.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Dogwood+Therapeutics%2C+++++For%3A+Mar+31/26500682.html Fri, 15 May 2026 09:21:00 -0400 DWTX O.00793356 http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Dogwood+Therapeutics%2C+++++For%3A+Mar+31/26500682.html si-local-file:///var/storage/secattach/20260515/26500682.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Dogwood+Therapeutics%2C+++++For%3A+Mar+31/26500682.html Fri, 15 May 2026 09:21:00 -0400 DWTX O.00793356 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Dogwood+Therapeutics%2C+++++For%3A+May+14/26490849.html si-local-file:///var/storage/secattach/20260514/26490849.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Dogwood+Therapeutics%2C+++++For%3A+May+14/26490849.html Thu, 14 May 2026 08:50:00 -0400 DWTX O.00793356 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Dogwood+Therapeutics%2C+++++For%3A+May+14/26490849.html si-local-file:///var/storage/secattach/20260514/26490849.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Dogwood+Therapeutics%2C+++++For%3A+May+14/26490849.html Thu, 14 May 2026 08:50:00 -0400 DWTX O.00793356 http://www.streetinsider.com/Press+Releases/Dogwood+Therapeutics+Announces+First+Quarter+2026+Financial+Results/26490591.html <p align="center">- <em>Halneuron</em><em>®</em> <em>Phase 2b trial in Chemotherapy Induced Neuropathy on track for top-line results in fall 2026 -</em></p> <p align="center"><em>- FDA acceptance of SP16 Investigational New Drug Application for the treatment of Chemotherapy Induced Pain and Neuropathy –</em></p> <p align="center">- <em>Announces Worldwide Development and Commercialization Partnership for Legacy Antiviral Assets with potential value up to $100M to Dogwood and its current and former shareholders -</em></p> <p align="justify">ALPHARETTA, Ga., May 14, 2026 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (“Dogwood” or the “Company”), a company that focuses on developing first-in-class, new non-opioid medicines to treat http://www.streetinsider.com/Press+Releases/Dogwood+Therapeutics+Announces+First+Quarter+2026+Financial+Results/26490591.html Thu, 14 May 2026 08:30:00 -0400 A.50216777 A.60001765 DWTX O.00793356 O.20738543 O.54516537